Evidence mapPaperPMID 34829888Full record

ReviewBiomedicines2021

MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective.

Miguel A Ortega, Miguel Angel Alvarez-Mon, Cielo García-Montero, Oscar Fraile-Martinez, Guillermo Lahera, Jorge Monserrat, Luis Muñoz-Merida, Fernando Mora, Roberto Rodríguez-Jiménez, Sonia Fernandez-Rojo and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Miguel A OrtegaDepartment of Medicine and Medical Specialities, University of Alcala, 28801 Alcalá de Henares, Spain.ORCID 0000-0003-2588-1708
Miguel Angel Alvarez-MonDepartment of Medicine and Medical Specialities, University of Alcala, 28801 Alcalá de Henares, Spain.
Cielo García-MonteroDepartment of Medicine and Medical Specialities, University of Alcala, 28801 Alcalá de Henares, Spain.ORCID 0000-0001-6016-7855
Oscar Fraile-MartinezDepartment of Medicine and Medical Specialities, University of Alcala, 28801 Alcalá de Henares, Spain.ORCID 0000-0002-4494-6397
Guillermo LaheraDepartment of Medicine and Medical Specialities, University of Alcala, 28801 Alcalá de Henares, Spain.ORCID 0000-0002-6152-3564
Jorge MonserratDepartment of Medicine and Medical Specialities, University of Alcala, 28801 Alcalá de Henares, Spain.ORCID 0000-0003-1775-4645
Luis Muñoz-MeridaDepartment of Medicine and Medical Specialities, University of Alcala, 28801 Alcalá de Henares, Spain.
Fernando MoraCancer Registry and Pathology Department, Hospital Universitario Principe de Asturias, 28806 Alcalá de Henares, Spain.ORCID 0000-0003-4698-1679
Roberto Rodríguez-JiménezDepartment of Legal Medicine and Psychiatry, Complutense University, 28040 Madrid, Spain.
Sonia Fernandez-RojoCancer Registry and Pathology Department, Hospital Universitario Principe de Asturias, 28806 Alcalá de Henares, Spain.ORCID 0000-0003-0653-8808
Javier QuinteroCancer Registry and Pathology Department, Hospital Universitario Principe de Asturias, 28806 Alcalá de Henares, Spain.
Melchor Álvarez-MonDepartment of Medicine and Medical Specialities, University of Alcala, 28801 Alcalá de Henares, Spain.
Universidad de Alcalá · ESUniversidad Complutense de Madrid · ES

Funding

METHADONE TREATMENT: A STUDY OF A COUNTY POLICY CHANGER01DA003804 · SCIENTIFIC ANALYSIS CORPORATION · 1985 to 1989
Comunidad de Madrid B2017/BMD3804Instituto de Salud Carlos III PI18/01726
6 · The paper itself

Abstract

Major Depressive Disorder (MDD) represents a major global health concern, a body-mind malady of rising prevalence worldwide nowadays. The complex network of mechanisms involved in MDD pathophysiology is subjected to epigenetic changes modulated by microRNAs (miRNAs). Serum free or vesicles loaded miRNAs have starred numerous publications, denoting a key role in cell-cell communication, systematically and in brain structure and neuronal morphogenesis, activity and plasticity. Upregulated or downregulated expression of these signaling molecules may imply the impairment of genes implicated in pathways of MDD etiopathogenesis (neuroinflammation, brain-derived neurotrophic factor (BDNF), neurotransmitters, hypothalamic-pituitary-adrenal (HPA) axis, oxidative stress, circadian rhythms...). In addition, these miRNAs could serve as potential biomarkers with diagnostic, prognostic and predictive value, allowing to classify severity of the disease or to make decisions in clinical management. They have been considered as promising therapy targets as well and may interfere with available antidepressant treatments. As epigenetic malleable regulators, we also conclude emphasizing lifestyle interventions with physical activity, mindfulness and diet, opening the door to new clinical management considerations.

Indexed as

biomarkersinflammationMajor Depressive DisordermicroRNAs

Identifiers

PMID34829888
PMCPMC8615526
OpenAlexW3211397738

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.